Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 7 versus MONISTAT 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 7 versus MONISTAT 3.
MICONAZOLE 7 vs MONISTAT 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Miconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
One vaginal suppository (200 mg miconazole nitrate) intravaginally at bedtime for 3 consecutive days; or one applicatorful (5 g) of 4% vaginal cream intravaginally at bedtime for 7 days.
None Documented
None Documented
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Terminal elimination half-life is approximately 30 hours after topical vaginal application; prolonged in hepatic impairment.
Primarily fecal (~50%) and renal (~<1% unchanged)
Primarily fecal (97%) via biliary excretion; renal excretion of unchanged drug is negligible (<1%).
Category A/B
Category C
Antifungal
Antifungal